CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.

@article{Klein2014CD163II,
  title={CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.},
  author={Jonathan L. Klein and Tudung T Nguyen and Gabriel Alejandro Bien-Willner and Ling Chen and Kelley V. Foyil and Nancy L. Bartlett and Eric J. Duncavage and Anjum Hassan and John L Frater and Friederike H Kreisel},
  journal={American journal of clinical pathology},
  year={2014},
  volume={141 3},
  pages={
          381-7
        }
}
OBJECTIVES In recent years, research has increasingly focused on the microenvironment of classical Hodgkin lymphoma (CHL) as a predictor of treatment outcome. The focus of this study was to assess the interobserver reproducibility in interpreting macrophage-associated immunohistochemistry (IHC) for CD68 and CD163 in a retrospective cohort of 88 patients with CHL. METHODS Staining results were correlated with clinical outcome in all patients and those with a high international prognostic score… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Prognostic value of tumor-associated macrophages in classic Hodgkin ’ s lymphoma : systematic review and meta-analysis

Tao Jiang, Xiaomin Cheng, Yongqian Jia
  • 2016
VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Similar Papers

Loading similar papers…